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MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with
no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9g once daily) vs anticancer treatments alone
in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients’ choice. Sixty-six
colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer
therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point
analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3%,
Po0.01; new metastases: 7.6 vs 23.1%, Po0.01; deaths: 12.1 vs 31.7%, Po0.01). Survival analysis showed significant improvements in
the MSC group regarding progression-free (P¼0.0184) and overall survivals (P¼0.0278) probabilities. Survival predictors in Cox’s
proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more
than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.
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A fermented wheat germ extract (code name: MSC; brand
name: Avemar), standardised to methoxy-substituted benzoqui-
nones and registered in Hungary in the year 2002 as medical
nutriment (reg. no. 503), has recently been shown to induce
apoptosis, to inhibit carbon flow to nucleic acid synthesis
(Boros et al, 2001; Comı ´n-Anduix et al, 2002) and to induce
major histocompatibility complex (MHC) class I proteins’
downregulation (Fajka-Boja et al, 2002) in tumour cells. It has
also been published that the extract strongly inhibited the
development of azoxymethane-induced colon cancer in rats
(Zalatnai et al, 2001). In mice experiments, furthermore, the
combination of 5-fluorouracil (5FU) injection plus the orally
applied MSC was superior to 5FU alone in the inhibition of
liver metastases formation of colon cancer origin (Hidve ´gi et al,
1999). An open-label, multicentre cohort study was therefore
initiated to estimate the expected difference between the progres-
sion-free survivals of colorectal cancer patients receiving
anticancer treatments alone or anticancer treatments supplemen-
ted with MSC.
PATIENTS AND METHODS
An open-label comparative cohort trial has been conducted to
determine if the addition of MSC to surgery and radio- and/or
chemotherapy adds any therapeutic benefit compared to surgery
and radio- and/or chemotherapy alone.
To be eligible, patients had to have cytologically or histologically
documented colorectal cancer (Dukes A–D); a WHO performance
status of 0, 1 or 2; adequate organ functions; life expectation of at
least 6 months; and minimal age of 18 years. No restrictions were
made regarding the date of the diagnosis. Similarly, no restrictions
were made for prior radio- and/or chemotherapy, but all the
patients had to undergo curative surgery at the time of diagnosis of
their disease. This included complete removal of the primary
tumour with adequate lymphadenectomy. In cases of existing
distant metastatic lesions, indicated by preoperative investigations,
hepatic and/or lung resection had also been carried out. At the
time of the enrolment into this study, however, several patients
had already had measurable and inoperable metastatic disease.
Exclusion criteria were severe parenchymatous liver disease not
connected to the metastatic cancer; severe kidney failure;
respiratory insufficiency; history of severe cardiovascular disease;
history of other type of cancer; pregnancy; lactation. The Regional
Helsinki Committees approved the protocol, and all patients gave
written informed consent before entering into the study.
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lThe two cohorts of patients (MSC and ‘control’) were formed
according to the patients’ preference, since MSC was freely
available as an over-the-counter product. Patients were asked if
they prefer to take MSC, and thus enrolled in the MSC cohort.
Those patients who refused to take the preparation formed the
control cohort. The decision of treatment group assignment
according to patients’ preference was carried out on ethical basis,
that is, those patients who otherwise would take MSC, got it free,
and those who otherwise would not wish to take, served as control.
By this procedure, no direct randomisation or stratification was
performed. At the time of check-ups, control patients were always
routinely asked if they take any dietary supplement or medical
nutriment including MSC and, randomly chosen sera of these
patients were analysed for 2-methoxy-benzoquinone (MBQ) and
2,6-dimethoxy-benzoquinone (DMBQ) contents, which are specific
indicators of MSC administration. Patients answering ‘yes’ to the
question of taking MSC, or having benzoquinone-positive sera,
were excluded from the control cohort. The measurement of
absorption of methoxy-substituted benzoquinones (MBQ and
DMBQ), whose markers were in the form of glycosides in crude
wheat germ, and were liberated as aglycones by the process of
fermentation, served as a specific monitoring technique of MSC
administration, and thus also of compliance. Sample preparation
was carried out by solid-phase extraction of the sera, followed by
reversed-phase high-performance liquid chromatography. Markers
MBQ and DMBQ were detected by mass spectrometry using single-
ion recording. The compounds were analysed by atmospheric
pressure chemical ionisation. The detection limit was 2ng per
10ml serum. Besides this analytical monitoring, patients of the
MSC cohort had to account for the empty containers of the
nutriment before having received the new supply.
The survival analysis was chosen with power 1–b¼0.8¼80%
and with a significance level a¼0.05¼5%; for these options, using
the Freedman’s procedure, the minimal required sample size was
62 patients per group, assuming a disease-free survival probability
in the control group to be roughly equal to 50% at average follow-
up, and an estimated disease-free probability increased by 25% in
the MSC group, as deducible from previous animal studies, as well
as from early clinical experiences.
Beyond the anticancer therapy for the group of patients of the
MSC cohort, 9g of MSC, dissolved in 150ml of water, were taken
orally once daily uninterruptedly and continuously throughout the
study but, at least for more than 6 months. The treatment time was
measured as the interval between the first and the last visits
completed. Patients of the control cohort received the anticancer
treatments alone. The term ‘anticancer treatments’ stands for the
5-FU-based standard Mayo Clinic chemotherapy regimen and/or
radiation therapy following surgery.
All patients were evaluated at baseline, at the end of the first
month, and every 12 weeks afterwards. Evaluation included
assessment of all measurable lesions by imaging (radiographic,
ultrasonic or magnetic resonance) techniques, laboratory tests
(haematology, chemistry and urinalysis), physical examination
and data collection of treatment-related toxicities. Tumour
progression was defined as an increase of at least 25% in the
overall area of the tumour size or the appearance of any new
lesions. Deaths were also reckoned in progression. Time-related
events were measured from the date of diagnosis.
The primary end point of this study was to compare
progression-free survivals of the two cohorts. For this case, the
two-tailed, unstratified log-rank test (Kaplan–Meier method),
where Po0.05 indicates statistical significance, was used. For other
comparisons, the z-test, Mann–Whitney’s z-test, Fisher’s exact test
and Student’s t-test were applied.
For the analysis of the effects of different variables (age, sex,
disease staging, chemotherapy, radiotherapy, MSC administration)
on survival, Cox’s proportional hazards (PH) model was used. The
Cox PH assumptions for this analysis have been evaluated for the
six independent variables taken into account (see also Table 3) by
using the Schoenfeld residuals (Schoenfeld, 1982) of the general
form
ruj ¼ xuj  
P
k2Rj
xuk expðxk^ b bxÞ
P
k2Rj
expðxk^ b bxÞ
for each covariate xu, such that ruj is the difference between the
covariate value for the failed jth observation and the average of the
covariate values, weighted on the basis of estimated hazard from
the Cox model; the residual analysis carried out by means of the
generalised method, developed by Grambsch and Therneau (1994),
has shown no evidence of violations of Cox’s PH assumptions.
RESULTS
Between November 1998 and March 2001, 176 consecutive
colorectal cancer patients from three oncosurgical institutions (at
Uzsoki Teaching Hospital of Budapest, University of Szeged and
University of Debrecen, Hungary) entered the study. Medix CRO
Company independently collected data in the centres. The patients
had either new diagnosis of their cancer or arrived for routine
check-up of their previously diagnosed and treated disease. After
progression of their disease, six patients of the control cohort
started to take MSC on their own. These patients were not included
in the data analysis.
Characteristics of the patients are shown in Table 1. The two
cohorts were obviously not balanced due to the fact that treatment
assignment was directed by patients’ preference. The average age
of the patients in the control cohort was significantly higher than
that of the MSC one (66.1 vs 61.7 years; P¼0.004). In contrast, the
MSC patients had significantly more advanced disease stages
(Mann–Whitney probe: z¼4.618; Po0.001). As many as 27.3% of
the MSC patients already had stage IV of the disease (metastatic),
while this value for the control patients was only 3.8 % (Po0.001).
Moreover, the average length of time from diagnosis to the entry
into the study was significantly longer for the MSC cohort than for
the control cohort, 11.2 months and 1.1 months, respectively
(Po0.001). There was no significant difference between the
average length of time from diagnosis to the last visit completed
between the two cohorts, 29.6 months and 34.0 months,
respectively (Student’s t¼1.494; P¼0.137). There was also no
significant difference between the two cohorts in the number of
patients receiving chemotherapy (z¼1.819; P¼0.069). However,
significantly more patients of the control cohort had received
radiotherapy (z¼3.406; Po0.001). Except for mean age at entry, at
baseline the prognoses of the MSC patients were significantly
poorer than those of the control patients.
At end-point analysis, progression-related events (new recurrent
disease, new metastatic lesions, deaths) were significantly more
frequent in the control cohort (Table 2). Log-rank analyses
(Kaplan–Meier estimates) also showed significant differences in
favour of the MSC patients in the cumulative probabilities of both
progression-free and overall survivals (Figures 1 and 2).
Strong predictors of survival in a Cox’s proportional hazards
model (variable follow-up) were UICC stage and MSC treatment
only (Table 3).
The administration of the medical nutriment was safe. No
serious adverse event (NCI-CTC Grades 3–4) was observed.
Generally, the greatest disadvantage of this preparation came
from its rather unpleasant taste, but no violation of the compliance
was detected, and according to blood analyses, no variation in the
degree of absorption of MSC by the patients was found. With
respect to the MSC cohort, the following side effects of MSC (with
the absolute number of cases) were reported: diarrhoea (four),
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lnausea and vomiting (two), flatulence (one), repletion (one), soft
stool (one), constipation (one).
DISCUSSION
As far as we know, the present study is the first one in the
literature, which brings clinical data on the anticolorectal cancer
treatments supporting activity of a fermented extract of one of the
staple foods of mankind: wheat.
The study was carried out to analyse the results of the long-term
supportive administration of MSC to colorectal cancer patients.
There are shortcomings to this cohort trial design, which were
accepted on ethical bases. As a result of the patients’ preference-
driven patient allocation, the two cohorts became unbalanced, but
in favour of the control patients, regarding the prognostic factors
(except mean age). The unbalanced cohorts did not compromise
this data collection. Since the MSC cohort had worse prognostic
factors at the time of recruitment, it was considered that any
benefit detected over the control cohort could support the claim
that MSC might be beneficial to colorectal cancer patients. It could
be concluded that this wheat extract, in combination with surgery
plus radio/chemotherapy, may inhibit overall tumour progression,
including the formation of new metastases, and may prolong the
survival of colorectal cancer patients. The Cox’s regression analysis
identified UICC staging and the more than 6 months long MSC
administration as independent predictors of survival. The age of
the patients enrolled had no significant influence. As MSC was
given in combination and, for the majority (87%) of the radio/
chemotherapy-treated patients, simultaneous with radio/che-
motherapy, its effects could not be separated from the benefits
of the conventional treatment modalities, nor could the possibly
beneficial impact of MSC administration on previously applied
radio/chemotherapy be measured. It is interesting that similar to
its 70% neoplastic tumour-preventing effect in an experimental
Table 1 Baseline characteristics of the patients
MSC
(n¼66)
Control
(n¼104)
No. % No. %
Sex
Male 40 60.6 57 54.8
Female 26 39.4 47 45.2
Age
a (years)
Mean 61.7 66.1
Range 36–88 40–79
UICC classification of the disease
b
Stage I 5 7.6 20 19.2
Stage II 17 25.7 48 46.2
Stage III 26 39.4 32 30.8
Stage IV
c 18 27.3 4 3.8
Recurrent disease
d 4 6.1 1 1
Metastatic lesions
Overall
e 21 4
Liver
f 13 4
Lung
g 60
Other organs
h 20
Time from diagnosis to present evaluation
h (months)
Mean 29.6 34.0
Median 23.5 28.0
s.d. 15.8 20.2
s.e.m. 1.9 2.0
Range 7–71 7–61
Chemotherapy, number of patients received
h 43 65.2 53 51.0
Radiotherapy, number of patients received
i 18 27.3 56 53.8
Length of MSC treatment (months)
Mean 18.3
Range 7–31
aP¼0.004.
bMann–Whitney’s z¼4.618, Po0.001.
cPo0.001.
dNo significant
difference.
eFisher’s exact test: Po0.01.
fFisher’s exact test: Po0.01.
gFisher’s exact
test: Po0.01.
hNo significant difference.
iz¼3.406, Po0.001.
Table 2 Occurrence of progression-related events (end-point analysis)
MSC (n¼66) Control (n¼104)
No. % No. %
Patients with new recurrent disease
a 2 3.0 18 17.3
Patients with new metastatic lesions
a 5 7.6 24 23.1
Deaths
a 8 12.1 33 31.7
Overall patients with progression events
b 11 16.7 44 42.3
aPo0.01.
bPo0.001.
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Figure 1 Kaplan–Meier estimate of the cumulative probability of
remaining free from disease progression in colorectal cancer patients.
Log-rank test: w
2¼5.32; P¼0.0184.
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Figure 2 Kaplan–Meier estimate of the cumulative probability of overall
survival in colorectal cancer patients. Log-rank test: w
2¼4.66; P¼0.0278.
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lcolon carcinogenesis model (Zalatnai et al, 2001), in the present
study MSC decreased the risk of death among colorectal cancer
patients by nearly 70%. (see the exp(b) values listed in Table 3,
calculating the following: 100 (1–0.33)¼0.67¼67%).
Besides these observed benefits of supplemental MSC in human
colorectal cancer, it has recently been shown in a randomised trial
that this extract is also beneficial concerning disease progression
in stage III melanoma patients (Demidov et al, 2002). It has also
been reported that MSC supplementation improves quality of life
and alleviates fatigue in advanced lung cancer (Hidve ´gi et al, 2003).
MSC displays multiple effects on the immune system. The
downregulation of MHC class I molecules on the membrane
surface of the tumour cells by MSC increases the natural killer cell
activity against neoplastic cells (Fajka-Boja et al, 2002). The
upregulation of tumour necrosis factor alpha (TNF-a) secretion by
the MSC-treated macrophages increases the antitumour activity of
these cells (Telekes and Hidve ´gi, 2001). It is noteworthy that MSC
enhances the activity of two of the most effective anticancer
cellular immune mechanisms. It has also been shown that MSC
upregulates the expression of intercellular adhesion molecule-1
(ICAM-1) on the endothelial cells (Telekes and Hidve ´gi, 2001). It is
known that endothelial cells of the vasculature of human solid
tumours have a decreased expression of ICAM-1 compared to
normal endothelial cells’ tissue, and this phenomenon can be
considered as a tumour-derived escape mechanism since the
development of an efficient leukcocyte infiltrate of the tumour is
impaired (Griffioen et al, 1996). MSC not only induced the
production of ICAM-1 but also showed synergy with the similar
effect of TNF-a. These observations may, at least partly, explain the
antimetastatic effect of MSC.
It has also been demonstrated that MSC induces apoptosis of
cancer cells (Fajka-Boja et al, 2002). A recent study of the
underlying mechanism behind the programmed cell death induc-
tion effect of MSC has pointed to the involvement of poly(ADP-
ribose) polymerase cleavage and thus to the role of caspase-3,
which indicated that decreasing cell motility and therefore
inhibition of metastasis could also be direct consequences of
MSC treatment (Comı ´n-Anduix et al, 2002).
A further plausible hypothesis on the mechanism behind these
positive clinical findings might come from an experiment in which
MSC also showed significant therapeutic benefit in naive mice with
lupus (SLE). The extract ameliorated the disease, downregulated
the autoantibody production and increased Th1- and delayed Th2
responses (Ehrenfeld et al, 2001). The shifting of the Th1/Th2
balance towards an increased cellular immune response might
have positive consequences in the mentioned human cancers.
Quite apart from its immunological effects, MSC has been shown
to selectively and dose-dependently inhibit nucleic acid ribose
synthesis in cancer cells through the regulation of enzymes
involved in the nonoxidative steps of the pentose cycle, while
increasing direct glucose carbon oxidation toward fatty acid
synthesis (Boros et al, 2001, 2002; Cascante et al, 2002). Decreased
substrate carbon flow through the pentose cycle toward nucleic
acid synthesis in response to MSC treatment of cancer cells may
also lead to a shortage of reducing equivalents that are
indispensable for the reduction of ribonucleotides to deoxyribo-
nucleotides during the replication of DNA (Comı ´n-Anduix et al,
2002). The simultaneous decrease both in nucleic acid synthesis
from glucose-derived ribose and in DNA replication may lead to a
decrease in cancer cell proliferation, which may explain the slow
disease progression and the increased survival rate in the MSC
cohort.
It is likely that the combination of these mechanisms will
provide enough theoretical basis to explain the supportive value of
the fermented wheat germ extract in the treatment of colorectal
cancer.
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